EFFECT OF OMACOR ON THE MORPHOLOGICAL STATUS OF VENOUS BYPASSES IN PATIENTS WITH CORONARY HEART DISEASE AFTER MYOCARDIAL REVASCULARIZATION


Cite item

Full Text

Abstract

The increasing number of aorto-coronary bypass grafts surgeries demands to develop new options and methods of treating this category of patients. According to up to date concepts patients after CABG are exposed to different risk factors and needed to be treated using modern approaches to reduce the progression of coronary artery disease and its complications. New drugs such as ω-3 unsaturated fatty acids are known to improve the outcomes after performed CABG surgery. This article analyses the place of Omacor in the complex treatment of these patients before CABG. According to performed study the therapy of omacor 2 g daily during 14 days before surgery was associated with reduction of intimal hyperplasia of venous conduits. In addition, the number of smooth muscle cells and proliferation index were also significantly reduced according to performed immunochemistry investigation. Based on this study, antiproliferative activity of Omacor may improve the viability of venous conduits in long terms.

References

  1. Беленков Ю.Н., Акчурин Р.С., Савченко А.П. Рентгеноморфологическая характеристика поражения шунтов у больных ишемической болезнью сердца после операции аортокоронарного шунтирования // Кардиология 2000. № 1. С. 6-12.
  2. Ардашев А.В., Коков Л.С., Синицын В.Е. Обследование и рентгенохирургическое лечение больных после операции аортокоонарного шунтирования. Медпрактика-М., 2007.
  3. Fitzgibbon GM, Kafka HP, Leach AJ. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
  4. Motwani JG, Topol EJ. Aortocoronary Saphenous Vein Graft Disease: Pathogenesis, Predisposition, and Prevention. Circulation 1998;97:916-31.
  5. Hassantash SA, Bikdeli B, Kalantarian S, et al. Pathophysiology of Aortocoronary Saphenous Vein Bypass Graft Disease Asian Cardiovasc Thorac Ann 2008;16:331-36.
  6. Donald S. Baim Percutaneous Treatment of Saphenous Vein Graft Disease. The ongoing challenge JACC 2003;42(8):1370-2.
  7. Bang H, Dyerberg J, et al. The composition of the Eskimo food in Northwestern Greenland. Am J Clin Nutr 1980;33:2657-66.
  8. Marchioli R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the GISSI-Prevenzione. Circulation 2002;105:1897-1903.
  9. Calo L, Bianconi L, Collivicchi F, et al. Рrevention of atrial fibrillation by n-3 polyunsaturated fatty acids after coronary artery bypass grafting. J Am Coll Cardiol 2005;45:1723-28.
  10. Harris W, Reid K, Sands S, et al. Red blood cell omega-3 fatty acids in acute coronary syndrome patients. Circulation 2007;115(8):267.
  11. Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Available at www.escardio.org/guidelines
  12. Панов А.В., Гордеев М.Л., Нильк Р.Я. и др. Применение омакора для предупреждения фибрилляции предсердий после хирургической реваскуляризации миокарда (Исследование АКСИОМА) // Артериальная гипертензия 2008. № 14. C. 162-64.
  13. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-68.
  14. Balashov KE, Rottman JB, Weiner HL, et al. CCR5 and CXCR3 T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-78.
  15. Balasingam V, Tejada-Berges T, Wright E, et al. Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J Neurosci 1994;14:846-56.
  16. Balding CE, Howie AJ, Drake-Lee AB, et al. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001;125:332-39.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies